Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. News
Palvella Therapeutics, Inc. Quantitative Score
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Palvella Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Palvella Therapeutics, Inc. Financials
Table Compare
Compare PVLA metrics with: | |||
|---|---|---|---|
Earnings & Growth | PVLA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PVLA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PVLA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PVLA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Palvella Therapeutics, Inc. Income
Palvella Therapeutics, Inc. Balance Sheet
Palvella Therapeutics, Inc. Cash Flow
Palvella Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Palvella Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Wesley H. Kaupinen | Founder, President, Chief Executive Officer & Director |
| Kathleen Goin | Chief Operating Officer |
| Jeffrey Martini | Chief Scientific Officer |
| David W. Osborne | Chief Innovation Officer |
| Jason Burdette | SVP of CMC & Technical Operations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Wesley H. Kaupinen | Founder, President, Chief Executive Officer & Director | Male | 901.07K | |
| Kathleen Goin | Chief Operating Officer | Female | 1971 | 638.96K |
| Jeffrey Martini | Chief Scientific Officer | 1978 | 530.43K | |
| David W. Osborne | Chief Innovation Officer | 1961 | -- | |
| Jason Burdette | SVP of CMC & Technical Operations | Male | -- |
Palvella Therapeutics, Inc. Insider Trades
| Date | 27 Feb |
| Name | JENKINS GEORGE M |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 4000 |
| Date | 27 Feb |
| Name | HERON ELAINE J |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 2400 |
| Date | 18 Feb |
| Name | Goin Kathleen |
| Role | Chief Operating Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 2154 |
| Date | 18 Feb |
| Name | Goin Kathleen |
| Role | Chief Operating Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 2148 |
| Date | 18 Feb |
| Name | Goin Kathleen |
| Role | Chief Operating Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 3026 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 27 Feb | JENKINS GEORGE M | Director | Acquired | P-Purchase | 4000 |
| 27 Feb | HERON ELAINE J | Director | Acquired | P-Purchase | 2400 |
| 18 Feb | Goin Kathleen | Chief Operating Officer | Acquired | M-Exempt | 2154 |
| 18 Feb | Goin Kathleen | Chief Operating Officer | Acquired | M-Exempt | 2148 |
| 18 Feb | Goin Kathleen | Chief Operating Officer | Disposed | S-Sale | 3026 |